- CME reported record volumes average daily volume (ADV) in March reached 41.1 million contracts (+33% YoY), while the full first quarter averaged 36.2 million (+22% YoY), confirming strong demand for risk-hedging instruments.
- Activity increased across all major segments, including interest rate, commodities, and U.S. Treasury contracts, where open interest reached record levels.
- UBS raised its Q1 2026 EPS forecast to $3.38 (vs. $3.29 previously and $3.16 consensus), pointing to higher transaction revenues driven by rising volumes.
- At the same time, UBS maintains a Neutral rating and a $310 price target (around current levels), suggesting limited upside at current valuations.
- The bank notes that although volumes remain high, pricing pressure (including discount structures and product mix) is partly limiting revenue growth.
- UBS believes the current environment is supportive for results, but peak activity may already be behind us, implying tougher comparisons in the coming quarters.
- As a result, UBS prefers companies less dependent on volume-driven dynamics, which underpins its cautious stance on CME.
- Despite this, CME remains a strong momentum stock - shares are up approximately 14% YTD, despite the S&P 500 falling over 10% and nearly 20% in the past six months.
- Meanwhile, Raymond James maintains a more positive stance (Outperform), citing weakness in the competing FMX platform as a supportive factor for CME.
- Operational incidents remain a negative factor, including the temporary suspension of trading in metals and gas markets, which the company is still analyzing.
CME Group shares (CME.US, D1 interval)
CME Group remains a high-quality beneficiary of market volatility, although according to UBS, further upside potential is limited as favorable operating conditions have largely been priced in. The company benefits from record trading volumes in U.S. Treasuries, aggressive hedging activity in the S&P 500, and business diversification, while maintaining a near-monopolistic position across several large markets. Investors view it as a defensive stock with a high-quality business, strong management, and a strategy that effectively capitalizes on market uncertainty. From a technical perspective, the uptrend appears intact, although the stock may face short-term resistance — particularly around the $315–320 range. Key support currently stands near $280, where the 200-day EMA (red line) is located.
Source: xStation5
United Health Group – The Medicaid decision supports the price
US Open: Wall Street plunges as the Middle East escalation fears rise 📉Casey's will debut in S&P %00
Broadcom Shares Soar on Deals with Google and Anthropic!
Memory on Fire: Samsung’s AI-Powered Quarter Breaks Records
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
